Skip to main content

Table 4 Priorities stratified by site

From: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis

Variable

Aggregate

China

Japan

South Korea

Taiwan

Chi-squared p-value

 

Coef ( SE )

Coef ( SE )

Coef ( SE )

Coef ( SE )

Coef ( SE )

 

Monitoring at-risk populations

13.75***

9.17**

16.67***

17.08***

12.08***

0.20

 

(1.5)

(3.1)

(2.7)

(3.3)

(2.5)

 

Risk Assessment

5.42***

5.83*

0.83

7.08*

7.92**

0.18

 

(1.3)

(2.4)

(2.4)

(2.9)

(2.4)

 

Access to treatments

5.21***

10.83***

5.83*

1.25

2.92

0.11

 

(1.4)

(3.0)

(2.4)

(2.7)

(3.2)

 

National guidelines

8.96***

14.17***

10.00***

7.92**

3.75

0.02*

 

(1.4)

(2.8)

(3.3)

(2.7)

(2.0)

 

Research infrastructure

3.96**

4.17

6.67*

3.75

1.25

0.63

 

(1.4)

(2.5)

(2.8)

(2.5)

(3)

 

Centers of excellence

6.86***

5.83*

10.00***

6.25*

5.42*

0.60

 

(1.5)

(3.9)

(2.5)

(1.9)

(3.1)

 

Multidisciplinary management

8.33***

7.50**

11.67***

6.25*

7.92**

0.44

 

(1.4)

(2.4)

(2.1)

(3.4)

(2.7)

 

Clinician education

11.04***

7.50**

10.83***

15.42***

10.42***

0.15

 

(1.3)

(2.3)

(3.2)

(2.5)

(2.6)

 

Public awareness

8.13***

3.33

6.67*

11.25***

11.25***

0.11

 

(1.4)

(2.7)

(2.8)

(2.7)

(2.6)

 

Transplantation infrastructure

0.42

−8.33

5.83

−0.42

4.58

0.01**

 

(1.5)

(3.6)

(2.4)

(2.7)

(2.7)

 

Measuring Social Burden

5.21***

2.50

2.50

2.92

12.92***

0.04*

 

(1.4)

(2.5)

(2.7)

(2.4)

(3.1)

 
  1. *p<0.05, **p<0.01, ***p<0.001, aggregate model R 2 =0.269, p<0.001, stratified model R 2 =.320.